Glow-in-the-Dark dyes could catch esophageal cancer earlier

This study tests a new way to find early signs of esophageal cancer in people with Barrett's esophagus. Participants will receive two fluorescent dyes (bevacizumab-800CW and cetuximab-800CW) either by mouth or directly on the esophagus before a standard endoscopy. The goal is to see if this method can spot abnormal tissue that regular endoscopy might miss. About 25 adults with Barrett's esophagus (with or without dysplasia) will take part.